{"id":11403700,"date":"2026-07-15T05:52:30","date_gmt":"2026-07-15T02:52:30","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11403700"},"modified":"2026-08-27T14:20:54","modified_gmt":"2026-08-27T11:20:54","slug":"imraldi-40-mg-adalimumab","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/imraldi-40-mg-adalimumab\/","title":{"rendered":"Imraldi 40 mg: 7 Essential Safety Checks for Adalimumab"},"content":{"rendered":"<div dir=\"ltr\" style=\"text-align:left\">\n<h2 id=\"top\">Imraldi 40 mg (Adalimumab Biosimilar) Pre-filled Pen \u2014 Complete Guide<\/h2>\n<div style=\"background:#f5f0fa;border-left:4px solid #5b2d90;padding:16px;border-radius:8px\">\n<p><strong>Quick Answer:<\/strong> Imraldi 40 mg is a biosimilar TNF-alpha inhibitor containing adalimumab, approved across a broad range of inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn&#8217;s disease, and ulcerative colitis. It is injected under the skin on an indication-specific schedule; loading and maintenance doses must follow the specialist prescription and current local leaflet.<\/p>\n<\/div>\n<h2 id=\"key-facts\">Key Facts Table<\/h2>\n<table>\n<tr>\n<th>Item<\/th>\n<th>Details<\/th>\n<\/tr>\n<tr>\n<td>Active ingredient<\/td>\n<td>Adalimumab (biosimilar to originator adalimumab)<\/td>\n<\/tr>\n<tr>\n<td>Strength<\/td>\n<td>40 mg \/ 0.4 mL pre-filled syringe or pen<\/td>\n<\/tr>\n<tr>\n<td>Drug class<\/td>\n<td>Biosimilar \u2014 TNF-alpha inhibitor<\/td>\n<\/tr>\n<tr>\n<td>Main uses<\/td>\n<td>Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn&#8217;s disease, ulcerative colitis<\/td>\n<\/tr>\n<tr>\n<td>Typical dosing<\/td>\n<td>Specialist-defined by indication, age and weight; loading and maintenance schedules can differ<\/td>\n<\/tr>\n<tr>\n<td>Route<\/td>\n<td>Subcutaneous injection<\/td>\n<\/tr>\n<tr>\n<td>Storage<\/td>\n<td>Refrigerator 2\u20138\u00b0C; do not freeze; protect from light<\/td>\n<\/tr>\n<tr>\n<td>Prescription status<\/td>\n<td>Prescription only \u2014 specialist supervision<\/td>\n<\/tr>\n<\/table>\n<h2 id=\"short-desc\">Short Description<\/h2>\n<p>Imraldi 40 mg is a biosimilar version of adalimumab, a well-established TNF-alpha inhibitor. It offers the same mechanism, efficacy, and safety profile as the reference biologic across multiple approved inflammatory and autoimmune conditions, typically at a more accessible cost.<\/p>\n<h2 id=\"toc\">Table of Contents<\/h2>\n<ul>\n<li><a href=\"#intro\">Introduction<\/a><\/li>\n<li><a href=\"#what-is\">What Is Imraldi 40 mg?<\/a><\/li>\n<li><a href=\"#how-works\">How Does It Work?<\/a><\/li>\n<li><a href=\"#benefits\">Main Benefits<\/a><\/li>\n<li><a href=\"#use-cases\">Real Use Cases<\/a><\/li>\n<li><a href=\"#best-for\">Who Is It Best For?<\/a><\/li>\n<li><a href=\"#avoid\">Who Should Avoid It?<\/a><\/li>\n<li><a href=\"#how-to-use\">How to Use Correctly<\/a><\/li>\n<li><a href=\"#best-time\">Best Time to Use<\/a><\/li>\n<li><a href=\"#common-questions\">Common Questions Users Ask<\/a><\/li>\n<li><a href=\"#results-timeline\">Expected Results Timeline<\/a><\/li>\n<li><a href=\"#mistakes\">Common Mistakes<\/a><\/li>\n<li><a href=\"#myths\">Myths vs Facts<\/a><\/li>\n<li><a href=\"#interactions\">Drug Interactions<\/a><\/li>\n<li><a href=\"#contraindications\">Contraindications<\/a><\/li>\n<li><a href=\"#tests\">Required Tests<\/a><\/li>\n<li><a href=\"#nutrition\">What to Eat With It<\/a><\/li>\n<li><a href=\"#other-meds\">Effect on Other Medications<\/a><\/li>\n<li><a href=\"#see-doctor\">When To See a Doctor<\/a><\/li>\n<li><a href=\"#expert-tip\">NSL Expert Tip<\/a><\/li>\n<li><a href=\"#faq\">Conversational FAQ<\/a><\/li>\n<li><a href=\"#conclusion\">Conclusion<\/a><\/li>\n<\/ul>\n<hr>\n<h2 id=\"intro\">Introduction<\/h2>\n<p>Adalimumab remains one of the most widely used biologics in medicine, and biosimilars like Imraldi 40 mg have expanded access to this well-proven TNF-alpha inhibitor across the full range of its approved conditions. Rather than representing a new mechanism, Imraldi 40 mg offers the same clinical benefit as the original biologic, backed by rigorous comparability studies confirming equivalent efficacy and safety.<\/p>\n<hr>\n<h2 id=\"what-is\">What Is Imraldi 40 mg?<\/h2>\n<p>Imraldi 40 mg is a biosimilar medicinal product containing adalimumab, a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells. It is approved for the same broad range of indications as originator adalimumab, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, and inflammatory bowel diseases (Crohn&#8217;s disease and ulcerative colitis) in adults.<\/p>\n<hr>\n<h2 id=\"how-works\">How Does It Work?<\/h2>\n<p>Adalimumab binds to and neutralizes tumor necrosis factor-alpha (TNF-alpha), a cytokine that drives inflammation across a wide range of autoimmune and inflammatory conditions. By blocking TNF-alpha&#8217;s interaction with its cell-surface receptors, adalimumab interrupts the inflammatory cascade responsible for joint damage in arthritis, skin plaques in psoriasis, and intestinal inflammation in Crohn&#8217;s disease and ulcerative colitis.<\/p>\n<hr>\n<h2 id=\"benefits\">Main Benefits<\/h2>\n<ul>\n<li>Same proven mechanism and efficacy as originator adalimumab, confirmed through biosimilarity studies.<\/li>\n<li>Approved across a wide spectrum of inflammatory and autoimmune conditions.<\/li>\n<li>Established every-other-week dosing that many patients find manageable long-term.<\/li>\n<li>Can be used as monotherapy or combined with methotrexate or other immunomodulators.<\/li>\n<li>Self-injectable at home after training, using a pre-filled syringe or pen.<\/li>\n<li>Decades of real-world adalimumab safety data support its use across indications.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"use-cases\">Real Use Cases<\/h2>\n<ul>\n<li>A rheumatoid arthritis patient with inadequate response to methotrexate and other DMARDs.<\/li>\n<li>A psoriatic arthritis or ankylosing spondylitis patient needing systemic biologic control.<\/li>\n<li>A patient with moderate-to-severe plaque psoriasis who is a candidate for systemic therapy.<\/li>\n<li>A Crohn&#8217;s disease or ulcerative colitis patient with inadequate response to conventional immunosuppressants.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"best-for\">Who Is It Best For?<\/h2>\n<p>Adults with moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, or moderately-to-severely active Crohn&#8217;s disease or ulcerative colitis who have had an inadequate response to conventional therapy, under specialist care.<\/p>\n<hr>\n<h2 id=\"avoid\">Who Should Avoid It?<\/h2>\n<ul>\n<li>Anyone with hypersensitivity to adalimumab or excipients.<\/li>\n<li>Patients with active tuberculosis or other severe infections, including sepsis and opportunistic infections.<\/li>\n<li>Patients with moderate-to-severe heart failure (NYHA class III\/IV).<\/li>\n<li>Patients with untreated latent tuberculosis until prophylaxis has been initiated.<\/li>\n<li>Caution in patients with a history of demyelinating disease or malignancy \u2014 discuss your full history with your specialist.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"how-to-use\">How to Use Correctly<\/h2>\n<ol>\n<li>Follow the exact maintenance dose prescribed for your indication, age, weight and response; schedules are not identical for every condition.<\/li>\n<li>Some conditions (Crohn&#8217;s disease, ulcerative colitis) require a higher initial loading dose before transitioning to the standard maintenance schedule \u2014 follow your specialist&#8217;s specific regimen.<\/li>\n<li>Inject into the thigh or abdomen, rotating sites at least 1 inch from previous injection points.<\/li>\n<li>Let the syringe or pen reach room temperature before injecting, per the leaflet.<\/li>\n<li>Use each device once and dispose of it in a sharps container.<\/li>\n<li>Concomitant corticosteroids may be tapered gradually per your specialist&#8217;s clinical judgment once adalimumab takes effect.<\/li>\n<\/ol>\n<hr>\n<h2 id=\"best-time\">Best Time to Use<\/h2>\n<p>Choose a fixed day every two weeks for your injection and keep to it consistently; time of day is flexible. Marking your calendar or setting a reminder helps maintain the every-other-week rhythm, which is easy to lose track of compared to weekly dosing.<\/p>\n<hr>\n<h2 id=\"common-questions\">Common Questions Users Ask<\/h2>\n<p><strong>Is a biosimilar as effective as the original adalimumab?<\/strong> Yes \u2014 biosimilars like Imraldi 40 mg undergo rigorous studies demonstrating equivalent efficacy, safety, and quality to the reference biologic before approval.<\/p>\n<p><strong>Do all my conditions use the same dosing schedule?<\/strong> No. Loading and maintenance schedules vary by condition, age and weight; your specialist will specify the correct regimen.<\/p>\n<p><strong>Can I switch between adalimumab biosimilars?<\/strong> Switching is generally supported by regulatory guidance and clinical data, but should always be done under your specialist&#8217;s direction.<\/p>\n<hr>\n<h2 id=\"results-timeline\">Expected Results Timeline<\/h2>\n<table>\n<tr>\n<th>Period<\/th>\n<th>What to Expect<\/th>\n<\/tr>\n<tr>\n<td>2\u20134 weeks<\/td>\n<td>Early symptom improvement possible in some patients.<\/td>\n<\/tr>\n<tr>\n<td>8\u201312 weeks<\/td>\n<td>More complete response typically assessed; IBD patients evaluated for remission around week 8.<\/td>\n<\/tr>\n<tr>\n<td>Ongoing<\/td>\n<td>Every-other-week maintenance sustains disease control.<\/td>\n<\/tr>\n<tr>\n<td>Long term<\/td>\n<td>Periodic reassessment of continued benefit versus risk, as recommended for long-term biologic use.<\/td>\n<\/tr>\n<\/table>\n<hr>\n<h2 id=\"mistakes\">Common Mistakes<\/h2>\n<ul>\n<li>Confusing the loading-dose schedule (for IBD) with the standard every-other-week maintenance dose.<\/li>\n<li>Injecting too close to a previous injection site, increasing local irritation.<\/li>\n<li>Stopping treatment once symptoms improve without discussing it with your specialist.<\/li>\n<li>Skipping TB or infection screening before starting.<\/li>\n<li>Assuming a biosimilar is &#8220;weaker&#8221; than the original \u2014 comparability data shows equivalent effect.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"myths\">Myths vs Facts<\/h2>\n<table>\n<tr>\n<th>Myth<\/th>\n<th>Fact<\/th>\n<\/tr>\n<tr>\n<td>&#8220;Biosimilars are inferior copies of the original drug.&#8221;<\/td>\n<td>Biosimilars undergo extensive comparability testing and are approved only when shown to match the reference product&#8217;s efficacy, safety, and quality.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;All adalimumab products are dosed identically regardless of condition.&#8221;<\/td>\n<td>Dosing is indication-specific; some conditions use loading doses and maintenance intervals that differ by age, weight and response.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;Switching biosimilars is risky.&#8221;<\/td>\n<td>Switching between adalimumab biosimilars or to\/from the reference product is generally well supported by regulatory and clinical evidence when guided by a specialist.<\/td>\n<\/tr>\n<\/table>\n<hr>\n<h2 id=\"interactions\">Drug Interactions<\/h2>\n<ul>\n<li><strong>Methotrexate:<\/strong> commonly combined with adalimumab in rheumatoid arthritis for enhanced effect.<\/li>\n<li><strong>Azathioprine\/6-mercaptopurine:<\/strong> combination in Crohn&#8217;s disease has shown higher rates of malignancy and serious infection compared with adalimumab alone \u2014 discuss risks with your specialist.<\/li>\n<li><strong>Live vaccines:<\/strong> avoid during treatment; update vaccinations beforehand.<\/li>\n<li>Avoid combining with other biologics targeting the same or overlapping inflammatory pathways.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"contraindications\">Contraindications<\/h2>\n<p>Hypersensitivity to adalimumab or any excipient. Active tuberculosis or other severe infections including sepsis and opportunistic infections. Moderate-to-severe heart failure (NYHA class III\/IV).<\/p>\n<hr>\n<h2 id=\"tests\">Required Tests<\/h2>\n<ul>\n<li>Tuberculosis screening before starting.<\/li>\n<li>Hepatitis B screening, given TNF inhibitors can reactivate latent infection.<\/li>\n<li>Baseline cardiac assessment if heart failure history is present.<\/li>\n<li>Ongoing clinical assessment of disease activity and response to treatment.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"nutrition\">What to Eat With It<\/h2>\n<p>Imraldi 40 mg has no specific food interactions. A balanced, anti-inflammatory-leaning diet \u2014 rich in vegetables, whole grains, omega-3 sources, and adequate protein \u2014 supports overall management of inflammatory conditions. Patients with Crohn&#8217;s disease or ulcerative colitis should follow any specific dietary guidance from their gastroenterologist, since nutritional needs can vary significantly during disease flares versus remission.<\/p>\n<hr>\n<h2 id=\"other-meds\">Effect on Other Medications<\/h2>\n<p>As a biologic antibody, adalimumab does not act through liver enzyme pathways the way small-molecule drugs do. The main considerations are combining thoughtfully with other immunosuppressants (methotrexate is often beneficial; azathioprine combinations need risk discussion) and avoiding other biologics targeting overlapping inflammatory pathways unless specifically directed.<\/p>\n<hr>\n<h2 id=\"see-doctor\">When To See a Doctor<\/h2>\n<ul>\n<li>Signs of infection: persistent fever, night sweats, unexplained weight loss, or any severe infection.<\/li>\n<li>Symptoms of heart failure: shortness of breath, swelling in the legs, unusual fatigue.<\/li>\n<li>Signs of demyelinating disease: numbness, tingling, vision changes, weakness.<\/li>\n<li>Injection-site or allergic reactions: swelling, hives, difficulty breathing.<\/li>\n<li>No meaningful improvement after an adequate treatment trial.<\/li>\n<\/ul>\n<hr>\n<h2 id=\"expert-tip\">NSL Expert Tip<\/h2>\n<div style=\"background:#fdf2f7;border:1px solid #d63384;padding:14px;border-radius:8px\">\n<p><strong>Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist:<\/strong> Don&#8217;t let the word &#8220;biosimilar&#8221; create unnecessary doubt \u2014 Imraldi 40 mg went through the same rigorous approval standards confirming it matches the original adalimumab&#8217;s effect. Keep your every-other-week schedule exact, since this interval is easier to lose track of than weekly dosing, and make sure your TB and hepatitis screening is complete before your first injection.<\/p>\n<\/div>\n<hr>\n<h2 id=\"faq\">Conversational FAQ<\/h2>\n<p><strong>Is Imraldi 40 mg the same as Humira?<\/strong><br \/>Imraldi 40 mg is a biosimilar to originator adalimumab (Humira), containing the same active substance and demonstrating equivalent efficacy and safety in regulatory studies.<\/p>\n<p><strong>Do I need a loading dose?<\/strong><br \/>Loading doses are used for selected indications, while maintenance schedules vary; your specialist will specify the exact regimen.<\/p>\n<p><strong>Can I combine it with methotrexate?<\/strong><br \/>Yes, this is a common and often beneficial combination in rheumatoid arthritis, as directed by your specialist.<\/p>\n<p><strong>Is it safe for long-term use?<\/strong><br \/>Adalimumab has an extensive long-term safety record; your specialist will periodically reassess continued benefit and risk.<\/p>\n<p><strong>What if I have latent TB?<\/strong><br \/>Prophylaxis treatment is typically started before beginning Imraldi 40 mg, under your specialist&#8217;s guidance.<\/p>\n<hr>\n<hr>\n<h2 id=\"imraldi-40-mg-safety\">Imraldi 40 mg: essential safety checks<\/h2>\n<p><strong>Imraldi 40 mg<\/strong> contains adalimumab 40 mg in 0.4 mL. It is a biosimilar TNF inhibitor and must be initiated and supervised by an experienced specialist. Before treatment, patients are assessed for active infection and tuberculosis; hepatitis B risk, vaccinations, heart failure and neurological history are reviewed when relevant.<\/p>\n<ul>\n<li><strong>Imraldi 40 mg is injected under the skin<\/strong> after training.<\/li>\n<li>The dose and interval vary by diagnosis, age, weight and response; never copy another patient\u2019s schedule.<\/li>\n<li>Store the original carton at 2\u20138\u00b0C, protect it from light and never freeze it.<\/li>\n<li>Seek urgent advice for serious infection, allergic reaction or worsening heart failure symptoms.<\/li>\n<\/ul>\n<p>Read the <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imraldi\" rel=\"dofollow noopener\" target=\"_blank\">EMA Imraldi product information<\/a> and the <a href=\"https:\/\/www.medicines.org.uk\/emc\/product\/15898\/smpc\" rel=\"dofollow noopener\" target=\"_blank\">current Imraldi SmPC<\/a>. Explore related products in our <a href=\"https:\/\/nostylelike.net\/en\/product-category\/autoimmune-disease-treatments\/\">autoimmune disease treatments category<\/a>.<\/p>\n<p><em>This page is educational and does not replace the prescriber, pharmacist or the leaflet supplied with the pack.<\/em><\/p>\n<h2 id=\"conclusion\">Conclusion<\/h2>\n<p>Imraldi 40 mg brings the well-established benefits of adalimumab therapy \u2014 a proven TNF-alpha inhibitor across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and inflammatory bowel disease \u2014 through a biosimilar confirmed to match the original in efficacy and safety. With correct injection technique, appropriate screening, and consistent every-other-week dosing, it offers a reliable option for patients across this broad range of inflammatory conditions. It remains a prescription-only biologic requiring specialist supervision.<\/p>\n<div style=\"background:#f8f9fa;border:1px solid #dee2e6;padding:12px;border-radius:8px;font-size:0.9em\">\n<p><strong>Medically reviewed by:<\/strong> Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist, 25+ years of clinical experience.<\/p>\n<p><strong>Medical Disclaimer:<\/strong> This content is educational and not a substitute for professional medical advice. Imraldi is a prescription-only biosimilar biologic requiring specialist supervision and pre-treatment screening. Sources: European Medicines Agency (EMA) product information for Imraldi (adalimumab).<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Imraldi 40 mg\/0.4 mL is an adalimumab biosimilar TNF inhibitor for approved inflammatory conditions. Learn infection, TB, heart-failure, injection and refrigeration safety checks.<\/p>\n","protected":false},"featured_media":11404851,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[42048,41601],"product_tag":[],"class_list":["post-11403700","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory","product_cat-autoimmune-disease-treatments","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11403700"}],"version-history":[{"count":2,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403700\/revisions"}],"predecessor-version":[{"id":11404872,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403700\/revisions\/11404872"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11404851"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11403700"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11403700"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11403700"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11403700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}